Acetic Acid → 4-{6-[(3R)-1-Aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-2-bromo-phenylamine

HRID 970012Notes

Reaction equation

[N:1]12[CH2:8][CH2:7][CH:4]([CH2:5][CH2:6]1)[C@@H:3]([O:9][C:10]1[N:15]=[N:14][C:13]([C:16]3[CH:21]=[CH:20][C:19]([NH2:22])=[CH:18][CH:17]=3)=[CH:12][CH:11]=1)[CH2:2]2.CC(O)=O.[Br:27]N1C(=O)CCC1=O>CC#N>[N:1]12[CH2:8][CH2:7][CH:4]([CH2:5][CH2:6]1)[C@@H:3]([O:9][C:10]1[N:15]=[N:14][C:13]([C:16]3[CH:21]=[CH:20][C:19]([NH2:22])=[C:18]([Br:27])[CH:17]=3)=[CH:12][CH:11]=1)[CH2:2]2

Participants

Conditions

Temperature: 0 °C

Procedure

The product of Example 29F (150 mg, 0.5 mmol) was treated with HOAc (36 μL, 36 mg, 0.6 mmol) in MeCN (5 mL) at ambient temperature for 5 min. N-bromosuccinimide (Aldrich, 100 mg, 0.55 mol) in MeCN (5 mL) was then added to the above solution at 0° C. and stirred at 0° C. for 1 h. It was then concentrated under reduced pressure. The title compound was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 μm, 30×100 mm. Eluting Solvent, MeCN/H2O (NH4HCO3, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) (100 mg, yield, 53%). 1H NMR (300 MHz, CD3OD) δ 1.45-1.65 (m, 1H), 1.65-1.94 (m, 2H), 1.93-2.16 (m, 1H), 2.19-2.39 (m, 1H), 2.67-3.11 (m, 5H), 3.37-3.54 (m, 1H), 5.18-5.35 (m, 1H), 6.91 (d, J=8.5 Hz, 1H), 7.19 (d, J=9.2 Hz, 1H), 7.70 (dd, J=8.5, 2.0 Hz, 1H), 7.95 (d, J=9.5 Hz, 1H), 8.03 (d, J=2.0 Hz, 1H) ppm. MS (DCl/NH3): 375 (M+H)+, 377 (M+H)+.

Workup

concentrationIt was then concentrated under reduced pressure
customThe title compound was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 μm, 30×100 mm. Eluting Solvent, MeCN/H2O (NH4HCO3, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) (100 mg, yield, 53%)

Sources & evidence

ORD record: ord-d073b1e73a544b2e80eb8823cb329f70
Source dataset: uspto-grants-2007_12
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US07309699B2

Reaction notes

Loading…